Epidermal growth factor receptor (EGFR)-positive lung adenocarcinoma refers to tumors harboring activating EGFR mutations and are typically treated with EGFR-directed tyrosine kinase inhibitors. This evidence concerns the gene EGFR and lung adenocarcinoma.